High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$4.7M
$4,671,277
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
MAZE
S
Maze Therapeutics, Inc.
Bachrodt Amy
• Officer • SVP, Finance
10b5-1 SellΔOwn -22.2%
2026-03-02
$168,237
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 SellΔOwn -22.2%
|
2026-03-02 | $168,237 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 Sell
|
2026-03-02 | $57,774 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
Other
|
2026-03-02 | $52,100 | M | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Dandekar Atul
• Officer • CSBO
10b5-1 SellΔOwn -26.4%
2026-02-27
$171,967
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
10b5-1 SellΔOwn -26.4%
|
2026-02-27 | $171,967 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Dandekar Atul
• Officer • CSBO
10b5-1 SellΔOwn -20.8%
2026-02-27
$168,756
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
10b5-1 SellΔOwn -20.8%
|
2026-02-27 | $168,756 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
Other
|
2026-02-27 | $78,150 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
10b5-1 Sell
|
2026-02-02 | $4,723 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Bernstein Harold
• President
10b5-1 SellΔOwn -98.3%
2026-02-02
$275,271
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
President
10b5-1 SellΔOwn -98.3%
|
2026-02-02 | $275,271 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Bernstein Harold
• President
10b5-1 SellΔOwn -58.1%
2026-02-02
$383,816
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
President
10b5-1 SellΔOwn -58.1%
|
2026-02-02 | $383,816 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
Other
|
2026-02-02 | $156,300 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
10b5-1 Sell
|
2026-02-02 | $26,523 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 Sell
|
2026-02-02 | $34,321 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Bachrodt Amy
• Officer • SVP, Finance
10b5-1 SellΔOwn -22.9%
2026-02-02
$187,068
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 SellΔOwn -22.9%
|
2026-02-02 | $187,068 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 Sell
|
2026-02-02 | $8,830 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
Other
|
2026-02-02 | $1,626 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
Other
|
2026-02-02 | $50,474 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
10b5-1 Sell
|
2026-01-29 | $51,821 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
Other
|
2026-01-29 | $78,150 | M | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Dandekar Atul
• Officer • CSBO
10b5-1 SellΔOwn -20.8%
2026-01-29
$154,147
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
10b5-1 SellΔOwn -20.8%
|
2026-01-29 | $154,147 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Dandekar Atul
• Officer • CSBO
10b5-1 SellΔOwn -21.1%
2026-01-29
$126,022
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
10b5-1 SellΔOwn -21.1%
|
2026-01-29 | $126,022 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
Other
|
2026-01-22 | $26,019 | M | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Bachrodt Amy
• Officer • SVP, Finance
10b5-1 SellΔOwn -27.8%
2026-01-22
$227,612
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 SellΔOwn -27.8%
|
2026-01-22 | $227,612 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
Other
|
2026-01-22 | $26,081 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
10b5-1 Sell
|
2026-01-07 | $1,011,299Large | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Other
|
2026-01-07 | $30,166 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Other
|
2026-01-07 | $216,152 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
Other
|
2026-01-07 | $262,126 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
Equity Compensation
|
2026-01-07 | $0 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Equity Compensation
|
2026-01-07 | $0 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Equity Compensation
|
2026-01-07 | $0 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Equity Compensation
|
2026-01-07 | $0 | M | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Sohn Catherine A.
• Director
Discretionary Sell
2026-01-07
$1,052,785Large
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Director
Discretionary Sell
|
2026-01-07 | $1,052,785Large | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Other
|
2026-01-07 | $34,188 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Equity Compensation
|
2026-01-06 | $0 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Discretionary Sell
|
2026-01-06 | $96,270 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Other
|
2026-01-06 | $25,977 | M | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Discretionary Sell
|
2025-09-15 | $464,035 | S | Form 4 |